|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] Peru's pharmaceutical market remains small in relative terms – standing at an estimated US$666mn in 2007. Per capita drug expenditure is just US$23.1 due to a preference for cheap, non-equivalent branded generics called 'similares'. The market is forecast to reach US$850mn by 2012, representing a CAGR of just 5%. We expect the generics market in particular to exhibit strong growth as the implementation of a free trade agreement (FTA) with the US leads to a tougher stance on similares that should push patients towards legitimate generics. In December 2007, the Peru-US free trade agreement was finally signed by US President George Bush and Peruvian President Alan GarcÃa following its ratification by the US Congress in the previous month. Although the wording of the intellectual property (IP) right provisions in the bill were watered-down under pressure from the Democrat-controlled US Congress, the agreement should still allow the vast majority of US exports duty-free access to Peru. Consequently, it is the US generics industry that has made the most positive noises concerning the bill. Overall trade between the two countries reached US$9bn in 2006. For Q108, BMI has overhauled its Business Environment Ratings methodology. Under the new system, Peru is ranked last in the Americas regions on 39 points, just one point behind Venezuela. The small size of the drug market and unspectacular growth forecast serve to limit the potential returns. However, in terms of risk, the market is mid-ranking in the region due to an improving regulatory environment and stable political and economic environment. The government's 2008 budget, published in August, pledges a 28% increase in overall investment, with social services seeing steep rises. Higher tax revenues and a booming economy should allow continuing record budget surpluses. This should help GarcÃa push forward increased coverage under the unified and strengthened Seguro Integral de Salud (SIS) health insurance system. The key will be ensuring those newly enrolled in the scheme can actually access health services and obtain basic medicine. Opposition parties are questioning the view that GarcÃa handled the August 2007 earthquake and resulting health crisis admirably, citing HIV-infected blood transfusions and irregular health purchases that could see citizens returning to street protests. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummaryPeru: Pharmaceuticals & Healthcare Industry SWOT Peru Political SWOT Analysis Peru Economic SWOT Analysis Peru Business Environment SWOT Analysis Peru Business Environment SWOT Analysis Chapter 2 - Peru: Business Environment RankingBusiness Environment Ranking Economics - Long-Term Risk Politics - Long-Term Risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Peru: Market SummaryChapter 4 - Regulatory RegimeIntellectual Property Regime Pricing & Reimbursement Issues Other Regulatory Issues Industry Developments Healthcare Sector Pharmaceutical Sector Chapter 5 - Industry Forecast ScenarioOverall Market Forecast Table: Peru Drug Market Indicators Key Growth Factors - Industry Table: Health Expenditure Indicators Key Growth Factors - Macroeconomic Table: Economic Activity Indicators Prescription Market Forecast Table: Prescription Market Indicators OTC Market Forecast Table: OTC Market Indicators Generics Market Forecast Table: Generic Market Indicators Export/Import Forecasts Table: Import/Export Trends Other Healthcare Data Forecasts Table: Other Healthcare Data Forecasts Key Risks To BMI's Forecast Scenario Chapter 6 - Competitive LandscapeTable: Indigenous Peruvian Pharmaceutical Companies That Acquired GMP Accreditation in 2006 Profiles: Leading Multinationals Sanofi-Aventis Merck & Co GlaxoSmithKline (GSK) Novartis Pfizer Chapter 7 - Company MonitorIndigenous Manufacturer Profiles Farmaindustria Unimed Chapter 8 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Technical Process Pharmaceutical Industry Sources Chapter 9 - Latin America: Regional Market OverviewChapter 10 - Appendix: Regional Demographic DataWages (ave per annum), US$ Population Household Spending Per Capita, US$ Private Consumption Per Capita, US$ PPP Market Size, GDP, US$bn Chapter 11 - Country Snapshot: Colombia Demographic DataSection 1: Population Table: Demographic Indicators (2005) Table: Rural/Urban Breakdown Section 2: Education & Healthcare Table: Education Table: Healthcare: Vital Statistics Table: Healthcare: Expenditure Section 3: Labour Market And Spending Power Table: Employment Indicators Table: Consumption And Stratification Table: Wages Per Year
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Latin America Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of Latin American Pharmaceuticals & Healthcare Sources[TOP] BMI's Latin American Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceuticals industry associations, chambers of commerce and company reports. Information sources include: |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||